Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

LUCD - Lucid Diagnostics Inc.


IEX Last Trade
0.7575
-0.013   -1.663%

Share volume: 0
Last Updated: Thu 26 Dec 2024 03:29:09 PM CET
Surgical and Medical Instrument Manufacturing : 0.83%

PREVIOUS CLOSE
CHG
CHG%

$0.77
-0.01
-1.64%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
25%
Profitability 25%
Dept financing 25%
Liquidity 23%
Performance 25%
Company vs Stock growth
vs
Performance
5 Days
-2.14%
1 Month
-22.04%
3 Months
0.59%
6 Months
-7.92%
1 Year
-45.41%
2 Year
-36.83%
Key data
Stock price
$0.76
P/E Ratio 
-0.93
DAY RANGE
N/A - N/A
EPS 
-$1.05
52 WEEK RANGE
$0.68 - $1.58
52 WEEK CHANGE
-$46.92
MARKET CAP 
43.214 M
YIELD 
N/A
SHARES OUTSTANDING 
53.990 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
BETA 
0.27
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$410,259
AVERAGE 30 VOLUME 
$582,133
Company detail
CEO: Lishan Aklog
Region: US
Website: luciddx.com
Employees: 0
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Surgical and Medical Instrument Manufacturing
Sector: Manufacturing

Lucid Diagnostics Inc. focuses on patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux. The company was incorporated in 2018 and is based in New York, New York.

Recent news